Omega-3 fatty acids may prevent some forms of depression

Reports new study in Biological Psychiatry

2014-10-01

(Press-News.org) Philadelphia, PA, October 1, 2014 – Patients with increased inflammation, including those receiving cytokines for medical treatment, have a greatly increased risk of depression. For example, a 6-month treatment course of interferon-alpha therapy for chronic hepatitis C virus infection causes depression in approximately 30% of patients.

Omega-3 fatty acids, more commonly known as fish oil, have a long list of health benefits, including lowering the risk of heart disease and reducing triglyceride levels. These nutritional compounds are also known to have anti-depressant and anti-inflammatory properties.

Despite some recent negative findings, as their tendency to increase the risk for prostate cancer was proven and some of the putative health benefits were not replicated in large trials, omega-3's remain of high interest to the depression field, where several studies have suggested benefits for depression and other psychiatric disorders.

This led a group of international researchers, led by senior author Dr. Carmine Pariante, to conduct a randomized, double-blind, placebo-controlled study in order to carefully evaluate the effects of omega-3 fatty acids on inflammation-induced depression.

They recruited 152 patients with hepatitis C to participate, each of whom was randomized to receive two weeks of treatment with EPA, DHA, or placebo. EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are the two main omega-3 fatty acids in fish oil supplements.

Following the two-week treatment, the patients received a 24-week course of interferon-alpha treatment and were evaluated repeatedly for depression.

The researchers found that treatment with EPA, but not DHA or placebo, decreased the incidence of interferon-alpha-induced depression in patients being treated for hepatitis C.

Pariante, a Professor at the Institute of Psychiatry, Psychology & Neuroscience at King's College London, added, "The study shows that even a short course (two weeks) of a nutritional supplement containing one such omega-3 polyunsaturated fatty acid (EPA) reduced the rates of new-onset depression to 10%."

In addition, both EPA and DHA delayed the onset of depression, and both treatments were well tolerated, with no serious side effects.

"These new data provide promising support for omega-3 fatty acids to prevent depression, complementing other studies where omega-3's were found to enhance antidepressant treatment," said Dr. John Krystal, Editor of Biological Psychiatry.

EPA is considered an "endogenous" anti-inflammatory, and in previous work, also published in Biological Psychiatry, these same authors found that subjects with low levels of endogenous EPA in the blood were at higher risk of developing depression. Therefore, the authors speculate that this nutritional intervention restores the natural protective anti-inflammatory capabilities of the body, and thus protects patients from new-onset depression when inflammation occurs.

Although further work is still necessary and the findings must be replicated, these data indicate that omega-3 polyunsaturated fatty acids may be effective in preventing depression in a group of patients at high-risk of depression because of increased inflammation.

INFORMATION:

The article is "Omega-3 Fatty Acids in the Prevention of Interferon-Alpha-Induced Depression: Results from a Randomized, Controlled Trial" by Kuan-Pin Su, Hsueh-Chou Lai, Hui-Ting Yang, Wen-Pang Su, Cheng-Yuan Peng, Jane Pei-Chen Chang, Hui-Chih Chang, and Carmine M. Pariante (doi: 10.1016/j.biopsych.2014.01.008). The article appears in Biological Psychiatry, Volume 76, Issue 7 (October 1, 2014), published by Elsevier.

Notes for editors Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Seil Collins, Press Officer, Institute of Psychiatry, Psychology & Neuroscience, King's College London at seil.collins@kcl.ac.uk or (+44) 0207 848 5377 / (+44) 07718 697 176.

The authors' affiliations, and disclosures of financial and conflicts of interests are available in the article.

John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.

About Biological Psychiatry Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.

The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.

Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 5th out of 135 Psychiatry titles and 14th out of 251 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2013 Impact Factor score for Biological Psychiatry is 9.472.

About Elsevier Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

ELSE PRESS RELEASES FROM THIS DATE:

Power can corrupt even the honest

2014-10-01

When appointing a new leader, selectors base their choice on several factors and typically look for leaders with desirable characteristics such as honesty and trustworthiness. However once leaders are in power, can we trust them to exercise it in a prosocial manner? New research published in The Leadership Quarterly looked to discover whether power corrupts leaders. Study author John Antonakis and his colleagues from the University of Lausanne explain, "We looked to examine what Lord Acton said over 100 years ago, that 'Power corrupts and absolute power corrupts absolutely.'" To ...

Non-traditional donor lungs appear safe for transplant

2014-10-01

Chicago, October 1, 2014 – Patients receiving lungs from donors whose cause of death was asphyxiation or drowning have similar outcomes and long-term survival as patients receiving lungs from traditional donors, according to a study in the October2014 issue of the Annals of Thoracic Surgery. Key points: Lungs from donors whose cause of death was asphyxiation or drowning can be safely transplanted into patients with end-stage lung disease. Patient survival rates were not affected when lungs from cases involving asphyxiation and drowning were used. The researchers note ...

Strict blood sugar control after heart surgery may not be necessary

2014-10-01

Chicago, October 1, 2014 – Patients undergoing coronary artery bypass grafting (CABG) surgery may not have to follow a strict blood sugar management strategy after surgery, according to a study in the October 2014 issue of the Annals of Thoracic Surgery. Key points Liberal management of a patient's blood sugar levels following CABG surgery leads to similar survival and long-term quality of life as achieved through stricter blood sugar management. The findings applied to all patients, regardless of diabetes status. The results may encourage hospitals to consider ...

Child mortality falls worldwide, but not fast enough, study finds

2014-10-01

Despite advances, millions of children worldwide still die before their fifth birthday, with complications from preterm birth and pneumonia together killing nearly 2 million young children in 2013, according to a study led by the Johns Hopkins Bloomberg School of Public Health. Their report, published online Oct. 1 in The Lancet, examines what caused an estimated 6.3 million children under the age of five to die in 2013, one-third fewer than the 9.9 million estimated to have died around the world in 2000. While preterm births and pneumonia were also the top killers in ...

Medical discovery first step on path to new painkillers

2014-10-01

A major medical discovery by scientists at The University of Nottingham could lead to the development of an entirely new type of painkiller. A drug resulting from the research, published in the journal Neurobiology of Disease, would offer new hope to sufferers of chronic pain conditions such as traumatic nerve injury, for which few effective painkillers are currently available. The work, led by Dr Lucy Donaldson in the University's School of Life Sciences, in collaboration with David Bates, Professor of Oncology in the University's Cancer Biology Unit, focuses on a ...

'Stealth' nanoparticles could improve cancer vaccines

2014-10-01

Cancer vaccines have recently emerged as a promising approach for killing tumor cells before they spread. But so far, most clinical candidates haven't worked that well. Now, scientists have developed a new way to deliver vaccines that successfully stifled tumor growth when tested in laboratory mice. And the key, they report in the journal ACS Nano, is in the vaccine's unique stealthy nanoparticles. Hiroshi Shiku, Naozumi Harada and colleagues explain that most cancer vaccine candidates are designed to flag down immune cells, called macrophages and dendritic cells, that ...

'Smart' bandage emits phosphorescent glow for healing below

2014-10-01

WASHINGTON, Oct. 1—Inspired by a desire to help wounded soldiers, an international, multidisciplinary team of researchers led by Assistant Professor Conor L. Evans at the Wellman Center for Photomedicine of Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) has created a paint-on, see-through, "smart" bandage that glows to indicate a wound's tissue oxygenation concentration. Because oxygen plays a critical role in healing, mapping these levels in severe wounds and burns can help to significantly improve the success of surgeries to restore limbs and physical ...

New drug-delivery capsule may replace injections

2014-10-01

CAMBRIDGE, MA -- Given a choice, most patients would prefer to take a drug orally instead of getting an injection. Unfortunately, many drugs, especially those made from large proteins, cannot be given as a pill because they get broken down in the stomach before they can be absorbed. To help overcome that obstacle, researchers at MIT and Massachusetts General Hospital (MGH) have devised a novel drug capsule coated with tiny needles that can inject drugs directly into the lining of the stomach after the capsule is swallowed. In animal studies, the team found that the capsule ...

Public feels more negative toward drug addicts than mentally ill

2014-10-01

People are significantly more likely to have negative attitudes toward those suffering from drug addiction than those with mental illness, and don't support insurance, housing, and employment policies that benefit those dependent on drugs, new Johns Hopkins Bloomberg School of Public Health research suggests. A report on the findings, which appears in the October issue of the journal Psychiatric Services, suggests that society seems not to know whether to regard substance abuse as a treatable medical condition akin to diabetes or heart disease, or as a personal failing ...

Dog waste contaminates our waterways: A new test could reveal how big the problem is

2014-10-01

Americans love their dogs, but they don't always love to pick up after them. And that's a problem. Dog feces left on the ground wash into waterways, sometimes carrying bacteria — including antibiotic-resistant strains — that can make people sick. Now scientists have developed a new genetic test to figure out how much dogs are contributing to this health concern, according to a report in the ACS journal Environmental Science & Technology. Orin C. Shanks, Hyatt C. Green and colleagues explain that our waterways are susceptible to many sources of fecal contamination, including ...

LAST 30 PRESS RELEASES:

AI finds undiagnosed liver disease in early stages

The American Society of Tropical Medicine and Hygiene and the Bill & Melinda Gates Foundation announce new research fellowship in malaria genomics in honor of professor Dominic Kwiatkowski